Russell Investments Group Ltd. lowered its position in shares of Icon Plc (NASDAQ:ICLR) by 14.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 121,488 shares of the medical research company’s stock after selling 19,828 shares during the period. Russell Investments Group Ltd. owned approximately 0.22% of Icon worth $13,836,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. GRATRY & Co LLC increased its position in shares of Icon by 5.1% during the third quarter. GRATRY & Co LLC now owns 30,144 shares of the medical research company’s stock valued at $3,433,000 after acquiring an additional 1,474 shares in the last quarter. GSA Capital Partners LLP boosted its holdings in Icon by 116.3% in the second quarter. GSA Capital Partners LLP now owns 9,337 shares of the medical research company’s stock worth $913,000 after purchasing an additional 5,020 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Icon by 16.8% in the second quarter. Principal Financial Group Inc. now owns 448,115 shares of the medical research company’s stock worth $43,821,000 after purchasing an additional 64,456 shares during the last quarter. BT Investment Management Ltd purchased a new stake in Icon in the third quarter worth approximately $325,000. Finally, Wesbanco Bank Inc. boosted its holdings in Icon by 18.6% in the second quarter. Wesbanco Bank Inc. now owns 18,044 shares of the medical research company’s stock worth $1,765,000 after purchasing an additional 2,830 shares during the last quarter. 89.95% of the stock is owned by institutional investors.

Icon Plc (ICLR) opened at $116.55 on Friday. The firm has a market cap of $6,325.50, a price-to-earnings ratio of 22.42, a PEG ratio of 1.80 and a beta of 0.57. Icon Plc has a one year low of $73.76 and a one year high of $124.48. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.90 and a current ratio of 1.90.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.35 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.03. The business had revenue of $440.30 million for the quarter, compared to analysts’ expectations of $438.09 million. Icon had a net margin of 16.37% and a return on equity of 28.42%. The company’s revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the company posted $1.19 EPS. equities research analysts forecast that Icon Plc will post 5.36 earnings per share for the current fiscal year.

Several brokerages recently issued reports on ICLR. Zacks Investment Research cut shares of Icon from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. ValuEngine cut shares of Icon from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Jefferies Group raised their target price on shares of Icon from $122.00 to $132.00 and gave the stock a “buy” rating in a report on Monday, October 9th. Robert W. Baird restated a “buy” rating and issued a $123.00 target price on shares of Icon in a report on Thursday, October 12th. Finally, Barclays raised their target price on shares of Icon from $108.00 to $120.00 and gave the stock an “equal weight” rating in a report on Friday, October 27th. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $121.00.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/12/02/russell-investments-group-ltd-has-13-84-million-position-in-icon-plc-iclr.html.

About Icon

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Receive News & Stock Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related stocks with our FREE daily email newsletter.